300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Japan
Puerto Rico
Poland
Cameroon
Guernsey
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Ireland
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Argentina
Angola
Cyprus
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Bangladesh
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Hungary
Finland
Grenada
Israel
Lithuania
Honduras
Iceland
Liechtenstein
Cambodia
Lebanon
Mongolia
Peru
Slovenia
San Marino
Chile
Ukraine
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

Agriline

VC Fund

Bromsgrove, United Kingdom

Agriline is a VC fund in Bromsgrove focused on Health Care and Medical. Agriline is the investment vehicle owned by a trust of which Trendlines' controlling shareholder Vincent Tchenguiz.

Total investments:
15
Last investment:
Lead investor:
13%

Last updated:

Industries Agriline invests in

Health CareMedicalBiotechnologyMedical DeviceAgTech

Stages Agriline invests in

SeedSeries AVenture - Series UnknownFunding RoundDebt Financing

Countries Agriline invests in

Israel

Round sizes

Seed $1.3M–$7.5MSeries A $5M–$17MVenture - Series Unknown $2.2M–$16M

Round size

Seed
$1.3M–$7.5M
Series A
$5M–$17M
Venture - Series Unknown
$2.2M–$16M

Investment Focus

Industry

  • Health Care 6 (40%)
  • Medical 4 (27%)
  • Biotechnology 4 (27%)
  • Medical Device 4 (27%)
  • AgTech 2 (13%)
See all 13 industries →

Stage

  • Seed 5 (33%)
  • Series A 4 (27%)
  • Venture - Series Unknown 4 (27%)
  • Funding Round 1 (7%)
  • Debt Financing 1 (7%)

Investments

CompanyDescriptionRoundLinks
Vessi Medical, an Israeli medical device startup, brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). Vessi uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, requiring a costly hospital stay performed under general anesthesia, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life.Vessi's minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The company's patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT, reducing the need for hospital stay by providing in office or ambulatory treatment. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. $16.5M / Series A / Feb 14, 2024
Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability $14.5M / Series A / Jul 05, 2022
SetBone Medical develops a new bone cement for the treatment of VCF and primarily caused by osteoporosis. $1.6M / Debt Financing / Jan 26, 2022
FruitSpec provides yield estimation as a service. They come, they scan the orchard, and provide the reports. FruitSpec provides two types of report: The first report gives the number of fruits and the size distribution in a specific orchard. The second report uses a heat-map to show the distribution of fruit quantities in that orchard. $5M / Series A / Nov 16, 2021
Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%).Using Vensica’s device, the drug will be instilled in a quick, pain-free proceduresubsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates. $16M / Venture - Series Unknown / Nov 01, 2021
Fidmi Medical is an Israeli start-up company founded in 2014 that is dedicated to developing enhanced feeding devices that offer easy insertion, replacement, and removal. $2.2M / Venture - Series Unknown / Oct 11, 2021
CoreBone has developed a highly bioactive, 100% mineral, strong bone graft material for dental, orthopedic and spine applications. The patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals during their growth process, accelerating healing and providing better bone connectivity. CoreBone was founded by CEO OhadSchwartz and CTO Prof. Itzhak Binederman. It is one of the portfolio companies of The Trendlines Group. CoreBone has issued patents and substantial know-how in regard to growing coral for medical purposes. $3.7M / Venture - Series Unknown / Oct 04, 2021
AgroScout is developing an autonomous system that allows for quick and efficient detection and monitoring of specific diseases in an entire field.The AgroScout system combines data from multiple sensors (covering an entire field); external data from weather, satellite, local sensors; machine learning; and deep learning to accurately andautonomously detect, identify, and monitor diseases in the field. This data will be analyzed by AgroScout’s algorithms to detect and identify disease and pests. The resulting data will be uploaded to the cloud, and farmers will receive actionable insights on their computer or mobile phone notifying them of disease location and status, with recommendations for treatment. $7.5M / Series A / Aug 04, 2021
IBI-Ag is a biotechnology company developing a new class of bioinsecticides. IBI-Ag is focused on the discovery and development of new types of biological solutions that utilize environmentally friendly technology to control insects. IBI-Ag utilizes breakthrough technology to produce efficient, selective, and safe bio-insect control solutions.IBI-Ag technology is highly cost-effective due to its fermentation suitability enabling farmers to produce agricultural produce at a low cost. Seed / Jun 21, 2021
ViAqua Therapeutics Ltd develops drugs and therapeutics for aquaculture. The company was founded in 2014 and is based in Israel.ViAqua Therapeutics is developing the first orally administered treatment for aquaculture.The Company’s management bring a broad range of business development, technology development, management, and industrial biotechexperience. $4.3M / Venture - Series Unknown / Jun 09, 2021
See all 15 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Japan
Puerto Rico
Poland
Cameroon
Guernsey
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Ireland
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Argentina
Angola
Cyprus
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Bangladesh
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Hungary
Finland
Grenada
Israel
Lithuania
Honduras
Iceland
Liechtenstein
Cambodia
Lebanon
Mongolia
Peru
Slovenia
San Marino
Chile
Ukraine
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Agriline invest in?

Agriline invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Agriline's check size?

Agriline typically joins rounds of $1.3M–$7.5M at Seed, $5M–$17M at Series A and $2.2M–$16M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Agriline participates in.

When did Agriline last invest?

The most recent investment recorded for Agriline closed in Feb 2024. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Agriline Find emails